Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 18, 2007 Billy Fisher	Still Sleepless at Arena The drug company posts a wider third-quarter loss than a year ago. Investors, take note.
The Motley Fool July 20, 2007 Brian Orelli	Arena Keeps Burning the Cash The pipeline drugs being developed by Arena Pharmaceuticals hold promise, but it will be a while before, or if, the company shows a profit.
The Motley Fool October 26, 2006 Brian Lawler	Arena Stays in the Game Despite having only early-pipeline offerings, Arena gets a boost from Cramer. More conservative investors can wait until more clinical trial results are released, since there should still be plenty of upside left in the stock if trial results are positive enough.
The Motley Fool June 27, 2008 Brian Lawler	Vanda's Drug Draws a Yawn Shares of Vanda Pharmaceuticals have fallen more than 20% recently, even though the company said that its phase 3 clinical trial met its primary goal.
The Motley Fool November 17, 2006 Billy Fisher	Vanda Shareholders Sleeping Better The latest news on the company's insomnia drug boosts the stock.
The Motley Fool March 30, 2009 Brian Orelli	Hopes Fall Short for Arena Pharmaceuticals Arena Pharmaceuticals' obesity drug lorcaserin doesn't look like it's doing enough to be a marketing success -- and the results might not even be enough to get it past the Food and Drug Administration.
The Motley Fool September 17, 2010 Brian Orelli	Thanks for Nothing, Fen-Phen Arena gets knocked down despite a relatively clean side-effect profile.
The Motley Fool May 27, 2011 Brian Orelli	Don't Believe the Obesity Hype Meta-analysis data isn't going to help Arena Pharmaceuticals' obesity drug.
The Motley Fool September 14, 2010 Brian Orelli	42% Drop? Really? Tell Us Something We Didn't Know. Arena Pharmaceuticals gets knocked down for no good reason.
The Motley Fool September 18, 2009 Brian Orelli	Up, Down, Up. Is This Stock a Home Run or Not? Shares of Arena Pharmaceuticals have been on a roller coaster after word that the company would release data for its obesity drug.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool September 14, 2010 Luke Timmerman	Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug.
The Motley Fool November 14, 2011 Brian Orelli	Biotech Uncertainty = Big Upside Potential Aastrom's phase 2 and phase 3 trials don't match up.
The Motley Fool October 3, 2008 Brian Orelli	Merck Can't Fight the Munchies The pharma gives up on its anti-obesity drug.
BusinessWeek April 24, 2006 Arlene Weintraub	A Cephalon Vet Takes On Insomnia Jack Lief helped create Provigil, the elixir of wakefulness. But his startup is committed to helping people sleep.
The Motley Fool March 18, 2008 Brian Orelli	Lack of Side Effects Doesn't Fatten Arena Good safety data on its obesity drug fails to plump up Arena's stock price. Investors, take note.
The Motley Fool September 2, 2010 Brian Orelli	Fatter Wallet. Up 22%. Still Risky. After VIVUS' Qnexa was shot down at its FDA advisory panel, it's clear that Arena and Orexigen have an uphill battle in front of them.
The Motley Fool December 14, 2005 Stephen D. Simpson	Arena Fattens Wallets Positive phase 2 data sends the biotech's stock up big and raises hopes of a blockbuster.
Chemistry World June 28, 2012 Patrick Walter	FDA green lights new obesity drug Lorcaserin, which has been developed by US-based Arena Pharmaceuticals, in conjunction with Japan's Eisai, is the first obesity prescription medicine approved for 13 years.
Chemistry World June 14, 2012 Andrew Turley	Good signs for Merck & Co insomnia pill In Phase III trials, insomnia drug candidate suvorexant performed well, reducing the time patients needed to fall asleep and increasing the total time sleeping, with some patients benefitting from the very first night of treatment.
The Motley Fool September 17, 2009 Brian Orelli	Sleepless in Sanofi It's nothing but sleepless nights for sanofi-aventis, and there's no drug to cure it.
The Motley Fool December 30, 2011 Brian Orelli	Working Through the Obese To-Do List in 2011 Arena ends the year on an upswing.
BusinessWeek January 26, 2004 Arelene Weintraub	"Exploring New Paradigms in Sleep" Two top execs from Sanofi, maker of the popular drug Ambien, talk about the challenges of staying on top in the insomnia market.
BusinessWeek January 17, 2005 Weintraub & Barrett	Waking Up The Insomnia Market On Dec. 16, Sepracor Inc. won approval from the Food & Drug Administration to market Lunesta, a new sleep aid. Giddy investors pushed Sepracor's stock up 16%, to $60, in the two weeks following the news.
The Motley Fool August 31, 2005 Stephen D. Simpson	Sanofi-Aventis: A Mix of News The company gave investors a lot of information for the second quarter, with not all of it positive.
The Motley Fool March 14, 2008 Brian Orelli	Weighing In on Obesity Drugs Could investing in drugmakers that produce weight-loss drugs help fatten your wallet?
Nurse Practitioner January 2012 Hedges & Ruggiero	Treatment Options for Insomnia Nurse practitioners must be prepared to screen patients for this common sleep disorder as well as understand the latest treatment options for optimal patient outcomes.
The Motley Fool October 25, 2010 Brian Orelli	Arena's Boring News The Food and Drug Administration turned down Arena Pharmaceuticals' obesity drug, lorcaserin. Tell us something we didn't know.
The Motley Fool December 22, 2010 Brian Orelli	Arena Charges On It seems Fool readers were a little more optimistic about the timing of Arena Pharmaceuticals' resubmission of its obesity drug to the Food and Drug Administration than the company is.
The Motley Fool July 27, 2007 Tom Taulli	A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth.
The Motley Fool January 28, 2011 Brian Orelli	Arena's Obese To-Do List The Food and Drug Administration's laundry list for Arena Pharmaceuticals seems to be getting longer.
The Motley Fool July 2, 2010 Brian Orelli	Arena Got Taken A billion-dollar market and that's all the pharmaceuticals company could get?
Nurse Practitioner May 2010 Townsend-Roccichelli et al.	Managing sleep disorders in the elderly This article will provide an overview of sleep physiology in the aging population, identify common sleep disorders, and suggest pharmacologic and nonpharmacologic treatment options.
The Motley Fool January 4, 2012 Brian Orelli	This Biotech's Obese To-Do List Is Done Arena resubmits lorcaserin for FDA approval.
AskMen.com Kristen Armstrong	Insomnia Causes And Treatments Insomnia can wreak havoc on a person's life. Sufferers can try meditation, exercise or relaxation methods to alleviate symptoms and enjoy long, restful sleep on a nightly basis.
The Motley Fool December 22, 2010 Matt Koppenheffer	Arena Pharmaceuticals Shares Plunged: What You Need to Know Shares of biopharma company Arena Pharmaceuticals dipped as much as 13% in intraday trading on massive volume.
The Motley Fool April 26, 2007 Tom Taulli	Phase Forward's False Funk Ignore its stagnant shares -- new deals should continue this company's growth.
Nurse Practitioner August 2009 Fisher & Valente	Evaluating and managing insomnia Insomnia is the most frequent complaint in sleep disorders, and in the past, it had been viewed as a transient problem related only to other medical issues. That line of thought has changed
The Motley Fool March 30, 2011 Brian Orelli	This Share Count Might Need Some Obesity Meds Soon Arena gets some dilutive financing.
The Motley Fool October 27, 2006 Brian Lawler	Wake Up to Sepracor Its insomnia drug is taking hold, and sales of its other drug jumped, too. If Sepracor can slim down its marketing spending, earnings should skyrocket. Investors, take note.
The Motley Fool November 9, 2010 Brian Orelli	Arena Pharmaceuticals Scores Some Points Overall, the recent Bloom-DM study leaves Arena in a slightly better position than it was in before the data was released, but this battle to get lorcaserin approved is far from over.
The Motley Fool January 11, 2012 Dan Caplinger	Has Arena Pharmaceuticals Become the Perfect Stock? Since we looked at Arena Pharmaceuticals last year revenue has fallen back and debt-to-equity levels have soared.
The Motley Fool October 31, 2007 Brian Orelli	A Slimmer Sepracor The big-pharma company reduces its sales team after a government decision forces price cuts for one of its top drugs. Investors, take note.
The Motley Fool July 30, 2007 Brian Orelli	Why Sepracor Investors Can't Sleep Shares of the drug maker were hammered after the company announced lower than expected earnings and a not so bright future.
Managed Care November 2006 Martin Sipkoff	Successful Treatment of Insomnia Starts With Formulary Design Many insurers may not consider insomnia a serious health problem, but it costs employers a bundle in lowered productivity.
The Motley Fool September 12, 2007 Brian Orelli	Butterflies Move Eastward Sepracor and GlaxoSmithKline ink a deal to market Lunesta worldwide. The market in Europe for sleep aids last year was about $500 million, but only about a quarter of insomnia sufferers are on medication, so there's certainly room for the market to grow.
The Motley Fool January 31, 2007 Brian Lawler	No Snoozing for Sepracor The pharmaceutical sees troubling sales trends with a key product. Investors, take note.
The Motley Fool August 3, 2011 Brian Orelli	Arena Sheds a Few Pounds Off Its To-Do List The brain cancer issue seems to be rat specific.
The Motley Fool July 21, 2006 Brian Lawler	Sepracor Stays Alert Insomnia drug Lunesta's sales growth is anything but sleepy. Despite the shares' ups and downs, Sepracor's most recent earnings suggest that its performance remains admirably steady.